Clinical Trials Logo
NCT number NCT03495869
Study type Observational
Source Virginia Commonwealth University
Contact Mandy Adams, MA
Phone 804-828-3686
Email msadams@vcu.edu
Status Not yet recruiting
Phase
Start date April 2018
Completion date October 2018

Clinical Trial Summary

The overall goal of this project is to collect preliminary data on psychosocial measures and behavioral performance comparing individuals with Opioid Use Disorder, Cocaine Use Disorder, dual diagnosis of Opioid and Cocaine Use Disorder, and Healthy Controls in an effort to determine overall feasibility of a phenotypic "fingerprint" for cohorts of individuals with addictions for use during clinical trials.


Clinical Trial Description

There is profound heterogeneity of subjects in clinical studies of addictions, with patients being diagnosed by the primary substance of use. As a result, utilizing current DSM addictions classification leads to problems with signal detection and hamper the progress of the development of new drugs and treatments for substance use disorders (SUDs). Getting beyond the DSM-5 based definitions is necessary to "fingerprint" addiction phenotypes and endophenotypes, using machine-learning analyses of big data. A detailed in-depth assessment of addiction phenotypes (deep phenotyping) may also include neuroimaging..

In an effort to develop a "fingerprint" for addiction phenotypes, NIDA established a Workgroup to develop a phenotyping battery of tests and self-rated psychometric scales, supplemented by resting state fMRI to be administered to participants in any extramural clinical trial where addictions are assessed. The final phenotyping battery content was determined via consensus from both the selected experts- consultants group and the NIDA workgroup, and as such, the battery requires feasibility and validation study to finalize its content. The NIDA Phenotyping Assessment Battery (PhAB) covers six neurofunctional addiction domains: Metacognition, Interoception, Cognition/Executive Function, Reward/Incentive Salience, Emotion/Negative Emotionality, and Sleep/Circadian Rhythm. The PhAB is meant to be administered during a Phenotyping visit - an extension of a screening visit in any clinical trial addictions protocol. In addition to the PhAB, the group also developed an ancillary set of measures to be administered in conjunction with the PhAB in any addictions clinical trial during the Phenotyping visit. The Platform Instruments include structured interviews, diagnostic measures (e.g., MINI), self report scales of symptom severity (e.g., ASRS-ADHD, VAS-Pain), trauma history (CTQ), computer-administered measures of intelligence (e.g., Shipley), and substance use measures (FTND, Timeline Follow-back), etc. Clinical trial investigators would administer these scales and behavioral tasks in addition to protocol nonspecific assessments (e.g., demographics) and medical evaluations (e.g, medical history and physical exams, genotyping, and labs) which could be done at Screening.


Study Design


Related Conditions & MeSH terms


See also
  Status Clinical Trial Phase
Recruiting NCT03065049 - Transforming Recovery Through Exercise and Community N/A
Recruiting NCT03279562 - Patient Driven Recovery With Nalmefene and Coaching Phase 2
Enrolling by invitation NCT03402672 - AWAITS: A Web-based E-health Application for Active Illicit Opioid Users N/A
Enrolling by invitation NCT03411265 - RETAIN: Retaining Opioid Users Entering Medication Assisted Treatment and Encouraging HCV/HIV Testing N/A
Recruiting NCT03169816 - Lorcaserin in Combination With XR-Naltrexone for Relapse Prevention in Opioid Use Disorder Phase 2/Phase 3
Recruiting NCT03048643 - Combining Opioid Addiction Treatment Services With CARe for Infectious Endocarditis N/A
Not yet recruiting NCT03420313 - Interim Buprenorphine Treatment to Bridge Waitlist Delays: Stage II Evaluation Phase 2
Not yet recruiting NCT03365362 - A Trial of Directly Observed and Long-term Varenicline Phase 4
Completed NCT03174067 - Buprenorphine in the Emergency Department Phase 4
Recruiting NCT03398265 - Treatment Navigation for Opioid Use Disorder N/A
Enrolling by invitation NCT02599818 - Navigation Services to Avoid Rehospitalization (NavSTAR) N/A
Recruiting NCT03363243 - Advancing STOP: Self-regulation Therapy for Opioid Addiction and Pain N/A
Recruiting NCT03135886 - Project I Test: Implementing HIV Testing in Opioid Treatment Programs N/A
Recruiting NCT03113409 - Buprenorphine as Adjunct to Outpatient Induction Onto Vivitrol Phase 2/Phase 3
Not yet recruiting NCT03212794 - Initiating Substance Use Disorder Treatment for Hospitalized Opioid Use Disorder Patients. N/A
Not yet recruiting NCT03367234 - Patient-Centered Care for Opioid Use Disorders in Federally Qualified Healthcare Centers and Specialty Care Settings N/A
Recruiting NCT03254043 - Evaluating a Novel Medication Device for Methadone Dosing N/A
Recruiting NCT03057847 - Sofosbuvir/Velpatasvir in Postpartum Women With Opioid Use Disorder and Chronic Hepatitis C Infection Phase 4
Completed NCT03386591 - Comparison of Naloxone Pharmacokinetics Phase 1
Recruiting NCT03275350 - Comparing Treatments for HIV-Infected Opioid Users in an Integrated Care Effectiveness Study (CHOICES) Scale-Up Phase 2/Phase 3